Navigation Links
PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
Date:8/29/2013

SCHOFIELD, Wis., Aug. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

Studies show that thirty-seven percent of military veterans who are returning from combat zones suffer with migraine; this ratio is three to four times greater than that of the general population. These veterans with migraine are twice as likely to suffer Post-Traumatic Stress Disorder (PTSD). This creates a hardship for these veterans since the medications that are commonly used to treat PTSD are incompatible with the prescription medications currently used to treat migraine.

"The drug interactions between the PTSD medications and current prescription migraine treatments can be deadly," said Russ Mitchell, CEO of PuraMed BioScience. "We offer these veterans a highly effective alternative to treat their migraines since LipiGesic M has an excellent safety profile and has no reported drug interactions. It is important for veterans suffering both conditions to find treatment, since the symptoms of one will increase the symptoms of the other causing a vicious cycle. With LipiGesic M, veterans are now safe to treat migraine without having to sacrifice their treatment for PTSD."

LipiGesic M is an over-the-counter formulation of feverfew and ginger that has been clinically tested and found to provide rapid-relief from migraine headache and associated symptoms. When clinical trial results of LipiGesic M are compared to those of prescription medications, LipiGesic M is found to be as effective as the top-selling prescription migraine medication, but without the severe effects.

"We are honored that Armed Forces Network requested two interviews with us after they heard our broadcasts on the Big Biz Show," said Mitchell. "We know that LipiGesic M has been well received by the troops and has been battle tested on the frontlines in Afghanistan. It quickly became one of the most requested items in the care packages that were sent to the front. Since it does not cause severe or debilitating side effects, military personnel can take LipiGesic M and get back to the important work of defending our country."

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Patricia McMurtrie
PuraMed BioScience
1326 Schofield Avenue
Schofield, WI 54476
715-571-4910
patricia@puramedbioscience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
2. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
3. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
4. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
5. Sangamo BioSciences to Acquire Ceregene
6. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
7. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
8. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
9. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
10. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
11. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... and Markets has announced the addition of the "South Korean Proton ... report to their offering. ... The South Korean Proton Therapy Market is expected to almost triple ... Therapy Market for South Korea was valued at ... plays an important role in delivering comprehensive cancer care to children and ...
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... , March 29, 2017 Optometrists have ... as the highest standard in quality and care ... introduces its objective Wavefront-driven refraction technologies and process ... This enables an unprecedented level of refraction and ... vision relegated to Topgun Navy fighter pilots, but ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, ... high school and college students who have participated in the program every summer. ... is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells ... for attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, ... been recognized as the visionary leader in the training of physicians, scientists, and ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American National ... organization, which plans to publish the first ANSI-approved GMP standard for dietary ...
Breaking Medicine News(10 mins):